Department of Microbiology and Clinical Microbiology, Hacettepe University Medical Faculty, Ankara, Turkey.
J Infect Chemother. 2010 Oct;16(5):322-8. doi: 10.1007/s10156-010-0068-2. Epub 2010 May 7.
Accurate determination of resistance is important to ensure appropriate antimicrobial therapy in Stenotrophomonas maltophilia infections. This study was undertaken to evaluate the susceptibility results obtained by disc diffusion, E-test, Phoenix system, and reference agar dilution method and also to evaluate the in vitro activity of various antimicrobial combinations against multidrug-resistant S. maltophilia. Susceptibilities to several antimicrobial agents were determined by agar dilution, disc diffusion, and E-test according to the US Clinical Laboratory and Standards Institute (CLSI) guidelines. Results were also evaluated in the in Phoenix system for available agents. Twelve different antibiotic combinations were tested for synergy by the E-test method. Most synergic combinations were confirmed by microdilution checkerboard assay. Tigecycline, trimethoprim/sulfamethoxazole (TMP-SMX) and doxycycline were the most effective drugs against S. maltophilia. Poorest agreement was determined by disc diffusion and E-test against ticarcillin/clavulanate and ciprofloxacin (κ < 0.4), by disc diffusion against colistin (κ < 0.4), and by the Phoenix system against piperacillin/tazobactam (κ < 0.4). Based on these data, disc diffusion seems to be unreliable for ticarcillin/clavulanate, ciprofloxacin, and colistin; E-test for ticarcillin/clavulanate and ciprofloxacin; and the Phoenix system for piperacillin/tazobactam for S. maltophilia susceptibility testing. Synergistic activity was detected predominantly with TMP-SMX + ticarcillin/clavulanate and TMP-SMX + ceftazidime. TMP-SMX + ceftazidime synergy was also supported by the checkerboard method. However, TMP-SMX + ticarcillin/clavulanate combination revealed indifferent effect by the checkerboard assay. As ticarcillin/clavulanate and ciprofloxacin E-test results were beyond the acceptable correlation limits, synergy testing performed with these agents was considered as unreliable. Further studies are required to standardize susceptibility testing, especially for colistin, ticarcillin/clavulanate, and ciprofloxacin for S. maltophilia. TMP-SMX-containing drug combinations seemed to be more synergistic on multidrug-resistant S. maltophilia; however, these results merit further evaluation.
准确测定耐药性对于确保嗜麦芽窄食单胞菌感染的适当抗菌治疗非常重要。本研究旨在评估纸片扩散法、E 试验、Phoenix 系统和参考琼脂稀释法获得的药敏结果,并评估各种抗菌药物组合对多药耐药嗜麦芽窄食单胞菌的体外活性。根据美国临床实验室标准化协会(CLSI)指南,通过琼脂稀释法、纸片扩散法和 E 试验测定了几种抗菌药物的敏感性。结果还在 Phoenix 系统中评估了现有药物的敏感性。采用 E 试验法对 12 种不同的抗生素组合进行了协同作用测试。大多数协同作用组合通过微量稀释棋盘试验得到证实。替加环素、复方磺胺甲噁唑(TMP-SMX)和多西环素是治疗嗜麦芽窄食单胞菌最有效的药物。替卡西林/克拉维酸和环丙沙星(κ<0.4)、多粘菌素(κ<0.4)纸片扩散法和哌拉西林/他唑巴坦(κ<0.4)Phoenix 系统对替卡西林/克拉维酸的测定结果一致性最差。基于这些数据,纸片扩散法似乎不可靠用于替卡西林/克拉维酸、环丙沙星和多粘菌素;E 试验法用于替卡西林/克拉维酸和环丙沙星;Phoenix 系统用于嗜麦芽窄食单胞菌药敏试验时,哌拉西林/他唑巴坦。主要检测到 TMP-SMX+替卡西林/克拉维酸和 TMP-SMX+头孢他啶的协同作用。TMP-SMX+头孢他啶的协同作用也得到了棋盘法的支持。然而,TMP-SMX+替卡西林/克拉维酸组合在棋盘试验中表现出无关效应。由于替卡西林/克拉维酸和环丙沙星 E 试验结果超出了可接受的相关性限制,因此认为这些药物的协同作用测试不可靠。需要进一步的研究来标准化药敏试验,特别是对嗜麦芽窄食单胞菌的多粘菌素、替卡西林/克拉维酸和环丙沙星。含 TMP-SMX 的药物组合对多药耐药嗜麦芽窄食单胞菌似乎更具协同作用;然而,这些结果值得进一步评估。